[Establishment of serum protein pattern model for screening pancreatic cancers by SELDI-TOF-MS technique]. 2008

Ning Ma, and Chun-lin Ge, and Feng-ming Luan, and Chao-jun Hu, and Yong-zhe Li, and Young-feng Liu
Department of General Surgery, the First Affiliated Hospital of China Medical University, Shenyang 110001, China.

OBJECTIVE To detect the serum specific proteins in pancreatic cancer patients and establish diagnostic model by surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) technique. METHODS Twenty-nine serum samples from patients of pancreatic cancer were collected before surgery and an additional 57 serum samples from age and sex matched individuals without cancer were used as controls, SELDI-TOF-MS technique and WCX magnetic beads were used to detect the protein fingerprint expression of all the serum samples and the resulting profiles between pancreatic cancer patients and controls were analyzed with biomarker wizard system, established the model using biomarker patterns system software. A double-blind test was used to determine the sensitivity and specificity of the classification model. RESULTS A panel of four biomarkers (relative molecular weight are 5705, 4935, 5318 and 3243 Da) were selected to set up a decision trees as the classification model for screening pancreatic cancer effectively. The result yielded a sensitivity of 100%, specificity of 97.4%. The double-blind test challenged the model with a sensitivity of 88.9% and a specificity of 89.5%. CONCLUSIONS SELDI-TOF-MS offers a unique platform for the proteomic detection of serum in pancreatic cancer patients. It also offers a noninvasive method to further study the proteomic changes in the development and progression of pancreatic cancer.

UI MeSH Term Description Entries
D008403 Mass Screening Organized periodic procedures performed on large groups of people for the purpose of detecting disease. Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D055088 Early Detection of Cancer Methods to identify and characterize cancer in the early stages of disease and predict tumor behavior. Cancer Screening,Cancer Screening Tests,Early Diagnosis of Cancer,Cancer Early Detection,Cancer Early Diagnosis,Cancer Screening Test,Screening Test, Cancer,Screening Tests, Cancer,Screening, Cancer,Test, Cancer Screening,Tests, Cancer Screening
D019032 Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization A mass spectrometric technique that is used for the analysis of large biomolecules. Analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. The matrix absorbs the laser energy, thus inducing a soft disintegration of the sample-matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. In general, only molecular ions of the analyte molecules are produced, and almost no fragmentation occurs. This makes the method well suited for molecular weight determinations and mixture analysis. Laser Desorption-Ionization Mass Spectrometry, Matrix-Assisted,MALD-MS,MALDI,Mass Spectrometry, Matrix-Assisted Laser Desorption-Ionization,Mass Spectroscopy, Matrix-Assisted Laser Desorption-Ionization,Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry,Spectroscopy, Mass, Matrix-Assisted Laser Desorption-Ionization,MALDI-MS,MS-MALD,SELDI-TOF-MS,Surface Enhanced Laser Desorption Ionization Mass Spectrometry,Laser Desorption Ionization Mass Spectrometry, Matrix Assisted,MALDI MS,Mass Spectrometry, Matrix Assisted Laser Desorption Ionization,Mass Spectroscopy, Matrix Assisted Laser Desorption Ionization,Matrix Assisted Laser Desorption Ionization Mass Spectrometry
D040901 Proteomics The systematic study of the complete complement of proteins (PROTEOME) of organisms. Peptidomics

Related Publications

Ning Ma, and Chun-lin Ge, and Feng-ming Luan, and Chao-jun Hu, and Yong-zhe Li, and Young-feng Liu
December 2006, Experimental oncology,
Ning Ma, and Chun-lin Ge, and Feng-ming Luan, and Chao-jun Hu, and Yong-zhe Li, and Young-feng Liu
January 2012, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.],
Ning Ma, and Chun-lin Ge, and Feng-ming Luan, and Chao-jun Hu, and Yong-zhe Li, and Young-feng Liu
January 2012, Asian Pacific journal of cancer prevention : APJCP,
Ning Ma, and Chun-lin Ge, and Feng-ming Luan, and Chao-jun Hu, and Yong-zhe Li, and Young-feng Liu
July 2009, Oncology reports,
Ning Ma, and Chun-lin Ge, and Feng-ming Luan, and Chao-jun Hu, and Yong-zhe Li, and Young-feng Liu
June 2012, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
Ning Ma, and Chun-lin Ge, and Feng-ming Luan, and Chao-jun Hu, and Yong-zhe Li, and Young-feng Liu
September 2007, Proteomics,
Ning Ma, and Chun-lin Ge, and Feng-ming Luan, and Chao-jun Hu, and Yong-zhe Li, and Young-feng Liu
June 2012, Molecular medicine reports,
Ning Ma, and Chun-lin Ge, and Feng-ming Luan, and Chao-jun Hu, and Yong-zhe Li, and Young-feng Liu
June 2011, Anatomical record (Hoboken, N.J. : 2007),
Ning Ma, and Chun-lin Ge, and Feng-ming Luan, and Chao-jun Hu, and Yong-zhe Li, and Young-feng Liu
March 2009, Proteomics. Clinical applications,
Ning Ma, and Chun-lin Ge, and Feng-ming Luan, and Chao-jun Hu, and Yong-zhe Li, and Young-feng Liu
December 2007, Journal of experimental & clinical cancer research : CR,
Copied contents to your clipboard!